Format

Send to:

Choose Destination
See comment in PubMed Commons below
Rev Med Suisse. 2013 Feb 6;9(372):315-8, 320.

[Thrombotic risk in myeloproliferative neoplasms: what the general practitioner needs to know].

[Article in French]

Author information

  • 1Service d'angiologie et d'hémostase HUG et Faculté de médecine de Geneve, 1211 Geneve 14. alessandro.casini@hcuge.ch

Abstract

Polycythaemia vera, essential thrombocythemia and primary myelofibrosis are stem cell-derived clonal haemopathies classified in the group of myeloproliferative neoplasms. Their clinical course may be complicated by both arterial and venous (sometimes in unusual sites) thrombotic events. Although general risk factors contribute to the prevalence of thrombotic events in this population, some other risk factors are specifically associated with the myeloproliferative neoplasms. The treatment options are aspirin, anticoagulation, cytoreduction and phlebotomies.

PMID:
23469399
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk